Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm
- PMID: 8589724
- DOI: 10.1038/ng0396-312
Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm
Abstract
Mastocytosis is characterized by accumulations of mast cells in various organs (1). Most cases are indolent and confined to the skin, where discrete mast cell infiltrates are associated increased epidermal melanin, a clinical picture known as urticaria pigmentosa (UP). Other forms of mastocytosis combine UP with aggressive involvement of other organs or with haemotologic abnormalities (1-4). It is not known whether all forms of mastocytosis are true neoplasms or whether some might represent reactive hyperplasias (5-7). The c-KIT proto-oncogene encodes a type III receptor tyrosine kinase (KIT) that is critical to the development and survival of mast cells and melanocytes (8-11). The ligand for KIT (KL) can stimulate mast cell development, proliferation, and mediator release (9,12-17), as well as melanocyte proliferation and pigment production (18-20). To determine the role of c-KIT in the pathogenesis of mastocytosis, we examined tissue and cells isolated from a patient with UP and aggressive systemic mastocytosis with massive splenic involvement. We found a mutation that results in constitutive activation and expression of c-KIT in mast cells of both skin and spleen. This is the first in situ demonstration of an activation c-KIT mutation in neoplastic cells. It also demonstrates the clonal and neoplastic nature of this form of mastocytes.
Similar articles
-
[Therapeutically relevant mutations in the receptor tyrosine kinase KIT in mastocytosis].Verh Dtsch Ges Pathol. 2007;91:169-76. Verh Dtsch Ges Pathol. 2007. PMID: 18314612 German.
-
Recent advances in the understanding of mastocytosis: the role of KIT mutations.Br J Haematol. 2007 Jul;138(1):12-30. doi: 10.1111/j.1365-2141.2007.06619.x. Br J Haematol. 2007. PMID: 17555444 Review.
-
Mastocytosis.Novartis Found Symp. 2005;271:232-42; discussion 242-9. Novartis Found Symp. 2005. PMID: 16605139 Review.
-
Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms.J Allergy Clin Immunol. 2010 Jun;125(6):1269-1278.e2. doi: 10.1016/j.jaci.2010.02.019. J Allergy Clin Immunol. 2010. PMID: 20434205
-
Mastocytosis: state of the art.Pathobiology. 2007;74(2):121-32. doi: 10.1159/000101711. Pathobiology. 2007. PMID: 17587883 Review.
Cited by
-
Advanced systemic mastocytosis: the impact of KIT mutations in diagnosis, treatment, and progression.Eur J Haematol. 2013 Feb;90(2):89-98. doi: 10.1111/ejh.12043. Eur J Haematol. 2013. PMID: 23181448 Free PMC article. Review.
-
High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia.Blood. 2008 May 1;111(9):4788-96. doi: 10.1182/blood-2007-07-101394. Epub 2008 Feb 5. Blood. 2008. PMID: 18252861 Free PMC article.
-
Gastrointestinal stromal tumours: an update.Sarcoma. 1998;2(3-4):133-41. doi: 10.1080/13577149877885. Sarcoma. 1998. PMID: 18521245 Free PMC article.
-
Loss of function of TET2 cooperates with constitutively active KIT in murine and human models of mastocytosis.PLoS One. 2014 May 2;9(5):e96209. doi: 10.1371/journal.pone.0096209. eCollection 2014. PLoS One. 2014. PMID: 24788138 Free PMC article.
-
Neuroimaging evidence of brain abnormalities in mastocytosis.Transl Psychiatry. 2017 Aug 8;7(8):e1197. doi: 10.1038/tp.2017.137. Transl Psychiatry. 2017. PMID: 28786975 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases